Efficacy of Intranasal Nanoemulsions in Rats
In an animal study, an intranasal formulation of dimethyl fumarate (DMF) achieved maximum cerebrospinal fluid (CSF) concentrations of approximately 8 µg/mL within 2 hours of administration in rats. Additionally, the formulation was characterized by optimal physicochemical properties, including a mean particle size of about 170 nm.
- Most relevant to
- Neurologist, Pharmacologist
Why it matters
These findings suggest that the intranasal delivery method may effectively enhance the exposure of DMF in the CSF, which is important for targeting neurological conditions.
What this does not prove
The study does not provide data from human clinical trials, so the findings are limited to animal models and cannot be directly applied to human treatment.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- No
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-16
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceIntranasal Delivery of Dimethyl Fumarate for MS Treatment ↗
Supporting passages (6)
randomizedNo
controlledNo
publication date2026-09-16
primary endpointIn the present study, a novel nanoemulsion (NE) formulation was developed and characterized with the aim of enhancing DMF exposure in the cerebrospinal fluid (CSF) following intranasal administration.
findingsIn rats, intranasal delivery achieved maximum CSF concentrations of ~8 µg/mL for DMF and ~1.5 µg/mL for GER within 2 h.
limitationsTitle: Mucoadhesive Nanoemulsions for Nose-to-Brain Delivery of Dimethyl Fumarate: Development, Characterization and Proof-of-Concept In Vivo Evaluation.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.